Legalize59765 laws
59765 laws
- § 356–1. Accelerated approval of priority countermeasures
- § 356–2. Accelerated approval Council
- § 357. Qualification of drug development tools
- § 358. Authority to designate official names
- § 359. Nonapplicability of subchapter to cosmetics
- § 360. Registration of producers of drugs or devices
- § 360bbb–5. Critical Path Public-Private Partnerships
- § 360bbb–5a. Emerging technology program
- § 360bbb–6. Risk communication
- § 360bbb–7. Notification
- § 360bbb–8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
- § 360bbb–8a. Optimizing global clinical trials
- § 360bbb–8b. Use of clinical investigation data from outside the United States
- § 360bbb–8c. Patient participation in medical product discussion
- § 360bbb–8d. Notification, nondistribution, and recall of controlled substances
- § 360ee. Grants and contracts for development of drugs for rare diseases and conditions
- § 360eee. Definitions
- § 360eee–1. Requirements
- § 360eee–2. National standards for prescription drug wholesale distributors
- § 360eee–3. National standards for third-party logistics providers
- § 360eee–4. Uniform national policy
- § 360ee–1. FDA rare neurodegenerative disease grant program
- § 360e–1. Pediatric uses of devices
- § 360e–3. Breakthrough devices
- § 360j. General provisions respecting control of devices intended for human use
- § 360jj. Studies by Secretary
- § 360kk. Performance standards for electronic products
- § 360l. Postmarket surveillance
- § 360ll. Notification of defects in and repair or replacement of electronic products
- §§ 1507 to 1513. Repealed. [Aug. 26, 1954, ch. 937](/us/act/1954-08-26/ch937), title V, § 542(a)(4), (6), (9)–(11), [68 Stat. 861](/us/stat/68/861)
- § 364c. Registration and product listing
- § 364d. Safety substantiation
- § 364e. Labeling
- § 364f. Records
- § 364g. Mandatory recall authority
- § 364h. Small businesses
- § 364i. Exemption for certain products and facilities
- § 364j. Preemption
- § 371. Regulations and hearings
- § 372. Examinations and investigations
- § 372a. Transferred
- § 379f. Recovery and retention of fees for freedom of information requests
- § 379g. Definitions
- § 379h. Authority to assess and use drug fees
- § 379h–1. Fees relating to advisory review of prescription-drug television advertising
- § 379h–2. Reauthorization; reporting requirements
- § 379i. Definitions
- § 379j. Authority to assess and use device fees
- § 379j–1. Reauthorization; reporting requirements
- § 379o. Environmental impact